| T17250 |
W-54011
|
405098-33-1
|
98%
|
|
|
W-54011 is a potent non-peptide C5a receptor antagonist. W-54011 inhibits the binding of 125I-labeled C5a to human neutrophils (Ki: 2.2 nM). W-54011 inhibits C5a...
|
| TP2296L |
TLQP 21 acetate
|
|
98%
|
|
|
TLQP 21 acetate is a potent agonist of G-protein-coupled receptor complement-3a receptor 1 (C3aR1). The EC50 values are 10.3 μM for mouse and 68.8 μM for human...
|
| T40646 |
Lipoteichoic acid
|
56411-57-5
|
98%
|
|
|
Lipoteichoic acid, a polymer of Staphylococcus aureus cell wall, activates the complement system by inducing C3 and inhibiting CD55, and reduces fat deposition v...
|
| T38332 |
Complement factor D-IN-2
|
1903742-34-6
|
98%
|
|
|
Complement factor D-IN-2 is an inhibitor of Complement factor D and reduces the excessive activation of complement factor D.
|
| T9316 |
JR14a
|
2411440-41-8
|
98%
|
|
|
JR14a (5-(Bis(4-chlorophenyl)methyl)-3-methylthiophene-2-carbonyl)-l-arginine hydrochloride) is a potent antagonist of human complement C3a receptor.
|
| T76867 |
Ravulizumab
|
1803171-55-2
|
98%
|
Ravulizumab
|
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity...
|
| T76831 |
Tesidolumab
|
1531594-08-7
|
98%
|
Tesidolumab
|
|
Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cuttin...
|
| T76702 |
Sutimlimab
|
2049079-64-1
|
98%
|
Sutimlimab
|
|
Sutimlimab is a novel monoclonal antibody targeting complement protein C1. Sutimlimab is commonly used as a C1 inhibitor to treat cold agglutina-associated hemol...
|
| T24524 |
NDT 9513727
|
439571-48-9
|
98%
|
|
|
NDT 9513727 is a potent, selective and competitive C5aR1 inverse agonist for the study of inflammatory and immune disorders.
|
| TP2180L |
Compstatin control peptide acetate
|
301544-78-5
|
98%
|
|
|
Compstatin control peptide acetate is an inhibitor of complement protein C3 by binding and inhibiting the cleavage of complement C3.
|
| T7497L |
C3a 70-77 2TFA(63555-63-5(free base))
|
T7497L
|
98%
|
|
|
C3a 70-77 2TFA(63555-63-5(free base)) (Complement 3a (70-77)) is an octapeptide corresponding to the COOH terminus of C3a.
|
| TP1304 |
Compstatin
|
206645-99-0
|
100%
|
|
|
Compstatin, a cyclic tridecapeptide, which was originally discovered from phage-display libraries, is a highly potent and selective C3 inhibitor.
|
| T7776 |
ADH-503
|
2055362-74-6
|
100%
|
|
|
ADH-503 (GB1275) is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression.
|
| T38287 |
C3a Receptor Agonist
|
944997-60-8
|
97.5%
|
|
|
C3a Receptor Agonist (C3a receptor agonist 1) binds the G protein-coupled C3a receptors (C3aRs) in the immune system complement pathway. Activation of C3aR preve...
|
| T0945 |
Cyclosporin A
|
59865-13-3
|
98%
|
|
|
Cyclosporin A is a naturally occurring cyclic polypeptide that is the active metabolite of a fungus. Cyclosporin A is an immunosuppressant that binds to procycli...
|
| T3638 |
Leukadherin-1
|
344897-95-6
|
98%
|
|
|
Leukadherin-1 is an allosteric activator of CD11b/CD18. Increasing CD11b/CD18-dependent cell adhesion to fibrinogen, Decreasing leukocyte motility and transendot...
|
| T9915 |
Eculizumab
|
219685-50-4
|
98.20%
|
Eculizumab
|
|
Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5
|
| T64388 |
3-Phenoxybenzaldehyde
|
39515-51-0
|
98.61%
|
|
|
3-Phenoxybenzaldehyde is a complement (classical pathway) inhibitor with IC50 of 1388μM.
|
| T13568L |
BCX 1470 hydrochloride
|
|
98.76%
|
|
|
BCX 1470 hydrochloride is a potent serine protease inhibitor with anti-inflammatory activity that inhibits the ester hydrolysis and haemolytic activity of factor...
|
| T12851 |
SB290157 trifluoroacetate
|
1140525-25-2
|
98.93%
|
|
|
SB290157 trifluoroacetate is a potent and selective antagonist of C3a receptor(IC50 of 200 nM).
|
